Losartan Potassium Tablet, Film Coated
Product Images NDC 42708-125

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium (NDC 42708-125). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Qpharma, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (42708 125 30)

Losartan Potassium Tablets USP, 25 mg film-coated tablets in a 30-count package. The label is from QPharma, Inc., with instructions to store at controlled room temperature and warnings to keep the container tightly closed and out of reach of children. It indicates prescription use only and notes the product is a sample not for sale.*

FDA Label Image

Figure1 (Losartan Fig1)

A line graph comparing the percentage of patients with primary endpoints over study months for Losartan Potassium and Atenolol. The graph shows time on the x-axis (0 to 66 months) and percentage of patients on the y-axis (0 to 16%). It includes an annotation indicating an adjusted risk reduction of 13% with a p-value of 0.021 for Losartan Potassium compared to Atenolol.*

FDA Label Image

Figure2 (Losartan Fig2)

A line graph comparing the percentage of patients with fatal or non-fatal stroke over time between Atenolol and Losartan Potassium treatments. The x-axis represents study months up to 66 months, and the y-axis shows the percentage of patients with stroke. The graph notes a 25% adjusted risk reduction with statistical significance (p=0.001).*

FDA Label Image

Figure 3 (Losartan Fig3)

A forest plot chart titled 'Primary Endpoint Events within Demographic Subgroups' comparing Losartan Potassium and Atenolol. It shows hazard ratios with 95% confidence intervals for primary composite and stroke (fatal/non-fatal) events across subgroups defined by age, gender, race, ISH, diabetes, and history of cardiovascular disease. The horizontal axis ranges from 0.3 to 3, indicating relative favorability between Losartan Potassium and Atenolol.*

FDA Label Image

Figure-4 (Losartan Fig4)

A line graph comparing the percentage of patients with events over 48 months between Losartan Potassium and placebo groups. The solid line represents Losartan Potassium, showing a lower percentage of events compared to the dashed placebo line. The graph includes text indicating a risk reduction of 16.1% with a p-value of 0.022.*

FDA Label Image

Chemical Structure (Losartan Str)

Chemical structure of losartan potassium depicted in a molecular diagram showing atomic connections and the potassium ion (K+).*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.